DESTINY-Breast07: T-DXd alone and in combination with pertuzumab is safe and effective in patients with HER2-positive metastatic breast cancer

SABCS 2025

Breast Cancer

DESTINY-Breast09: Favorable PROs with T-DXd plus pertuzumab in first-line HER2-positive advanced and metastatic breast cancer

SABCS 2025

Breast Cancer

DESTINY-Breast11: T-DXd followed by THP shows manageable and more favorable safety profile versus ddAC–THP in patients with high-risk HER2-positive early breast cancer

ESMO 2025

Breast Cancer

LBA1: DESTINY-Breast05: T-DXd significantly improves IDFS and DFS versus T-DM1 in HER2-positive early breast cancer with residual invasive disease

ESMO 2025

Breast Cancer

DESTINY-Breast09: T-DXd plus placebo shows superior efficacy over THP across subgroups in HER2-positive advanced or metastatic breast cancer

ESMO 2025

Breast Cancer

DESTINY-Breast11: Neoadjuvant T-DXd plus THP significantly improves pCR in high-risk HER2-positive early breast cancer

Breast Cancer

Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03

Ann Oncol

Saura C, Cortés J, Modi S, Kim SB, Hamilton E, Hurvitz SA, Krop IE, Curigliano G, Iwata H, Im SA, Herbolsheimer P, Karnoub M, Boran A, Kuwahara Y, Egorov A, André F

doi: 10.1016/j.annonc.2025.11.007

Breast Cancer

Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial

Ann Oncol

Harbeck N, Modi S, Pusztai L, Ohno S, Wu J, Kim SB, Yoshida A, Fabi A, Cao X, Joseph R, Li R, Żurawski B, Escrivá-de-Romaní S, Meneguetti R, Supavavej A, Chen SC, Liu Z, Kelly C, Curigliano G, Symmans WF, Gufran M, Ke J, Konpa A, Herbolsheimer P, Boileau JF, DESTINY-Breast11 Trial Investigators

doi: 10.1016/j.annonc.2025.10.019

CHICAGO 2025

Gastrointestinal Cancer

LBA4002: DESTINY-Gastric04: Improved OS with second-line T-Dxd versus ramucirumab plus paclitaxel in patients with HER2-positive metastatic GC/GEJA

SPECIAL REPORT

Breast Cancer

Related content

DESTINY-Breast09: Favorable PROs with T-DXd plus pertuzumab in first-line HER2-positive advanced and metastatic breast cancer

DESTINY-Breast11: T-DXd followed by THP shows manageable and more favorable safety profile versus ddAC–THP in patients with high-risk HER2-positive early breast cancer

LBA1: DESTINY-Breast05: T-DXd significantly improves IDFS and DFS versus T-DM1 in HER2-positive early breast cancer with residual invasive disease

DESTINY-Breast09: T-DXd plus placebo shows superior efficacy over THP across subgroups in HER2-positive advanced or metastatic breast cancer

DESTINY-Breast11: Neoadjuvant T-DXd plus THP significantly improves pCR in high-risk HER2-positive early breast cancer

Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03

Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial

LBA4002: DESTINY-Gastric04: Improved OS with second-line T-Dxd versus ramucirumab plus paclitaxel in patients with HER2-positive metastatic GC/GEJA

Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study